Pipeline

We are focused on the treatment of hemophilia using our high potency coagulation proteases that promote blood clotting. We plan to initiate two clinical trials in 2017, one in patients with hemophilia B and the other in hemophilia inhibitor patients.

Next Generation Hemostasis Programs

Hemophilia, Surgical Bleeding
Phase 1
    
Hemophilia B
Preclinical
    
FXa
Universal Pro-coagulant
Research
    
Drug Candidate
Indication
Research
Preclinical
Phase 1
Phase 2/3

*(formerly known as CB 813d)


Anti-Complement Assets

Asset

Indication

Anti-C3: CB 2782 Renal DGF, IRI cardiovascular
Anti-C3: Ophthalmic Dry AMD